Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.

Neeraj Narula Emily C L WongParambir S DulaiJohn K MarshallVipul JairathWalter Reinisch

Published in: The American journal of gastroenterology (2024)

Among moderate-severe CD patients, early and delayed responders to adalimumab and ustekinumab have similar one-year clinical outcomes. Biomarker decline can be observed through the initial 8 weeks of therapy in patients who will eventually be delayed responders which may help differentiate from non-responders.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
juvenile idiopathic arthritis
prognostic factors
ulcerative colitis
high intensity
early onset
metabolic syndrome
mesenchymal stem cells
bone marrow
glycemic control